Alkermes plc (ALKS) Stock
NASDAQ · ALKS
43.39
Fundamentals
Market cap
$7.28B
Price / Earnings ratio
118.5x
Price / Sales ratio
4.7x
Price / Book ratio
4.3x
Return on assets
0.1%
Ex-Dividend date
16 Nov 2023
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees2,050
CEOMr. Blair C. Jackson
IPO DateJul 16, 1991
HeadquartersDublin, Ireland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Blair C. Jackson | CEO & Director | 1973 |
| Mr. Joshua Reed M.B.A. | Senior VP & CFO | 1973 |
| Mr. David Joseph Gaffin J.D. | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 1972 |
| Dr. Craig C. Hopkinson M.D. | Executive VP of Research & Development and Chief Medical Officer | 1969 |
| Mr. Christian Todd Nichols | Senior VP & Chief Commercial Officer | 1970 |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & VP of Finance | 1975 |
| Mr. Tom Skoff | SVP & Chief Information Officer | — |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | — |
| Mr. Stephen Schiavo | Senior VP & Chief Human Resources Officer | — |
| Mr. Peter Norman | SVP of Policy, Government & Community Relations | — |
Fundamentals
Valuation
Market cap$7.28B
Price-to-sales ratio4.70
Price-to-book value4.33
Price-earnings ratio118.50
Return on Equity9.00%
Return on Sales0.15%
Return on Assets0.05%
PEG ratio1.96
Earnings Per Share
Earnings Per Share$0.40
Income Statement
Average volume1,402,513
EBITDA$276.38M
1 year high (52w)$55.67
1 year low (52w)$26.99
Dividend
Ex dividend date16 Nov 2023
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



